Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CardioMEMS, Inc.
Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.
Novel Anti-Hypertensive Treatment & NSCLC Drug Among New EU Filings
The European Medicines Agency has added five new drugs to its latest monthly list of medicines that are under review for potential EU marketing approval.
Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results
While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.
Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension
Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.